- Home
- ANTX vs RVPH Comparison
ANTX vs RVPH Comparison
Compare ANTX & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- RVPH
- Stock Information
- Founded
- ANTX 2017
- RVPH 2006
- Country
- ANTX United States
- RVPH United States
- Employees
- ANTX N/A
- RVPH N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- RVPH Health Care
- Exchange
- ANTX Nasdaq
- RVPH Nasdaq
- Market Cap
- ANTX 33.2M
- RVPH 26.6M
- IPO Year
- ANTX 2022
- RVPH N/A
- Fundamental
- Price
- ANTX $1.07
- RVPH $0.46
- Analyst Decision
- ANTX Buy
- RVPH Strong Buy
- Analyst Count
- ANTX 2
- RVPH 5
- Target Price
- ANTX $2.00
- RVPH $9.00
- AVG Volume (30 Days)
- ANTX 71.9K
- RVPH 3.2M
- Earning Date
- ANTX 08-12-2025
- RVPH 08-13-2025
- Dividend Yield
- ANTX N/A
- RVPH N/A
- EPS Growth
- ANTX N/A
- RVPH N/A
- EPS
- ANTX N/A
- RVPH N/A
- Revenue
- ANTX N/A
- RVPH N/A
- Revenue This Year
- ANTX N/A
- RVPH N/A
- Revenue Next Year
- ANTX N/A
- RVPH N/A
- P/E Ratio
- ANTX N/A
- RVPH N/A
- Revenue Growth
- ANTX N/A
- RVPH N/A
- 52 Week Low
- ANTX $0.87
- RVPH $0.30
- 52 Week High
- ANTX $2.73
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- ANTX 45.56
- RVPH 46.82
- Support Level
- ANTX $1.05
- RVPH $0.44
- Resistance Level
- ANTX $1.16
- RVPH $0.53
- Average True Range (ATR)
- ANTX 0.03
- RVPH 0.04
- MACD
- ANTX 0.00
- RVPH 0.02
- Stochastic Oscillator
- ANTX 18.87
- RVPH 56.07
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.